These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34835150)

  • 1. Predictive and Experimental Immunogenicity of
    Grund ME; Kramarska E; Choi SJ; McNitt DH; Klimko CP; Rill NO; Dankmeyer JL; Shoe JL; Hunter M; Fetterer DP; Hedrick ZM; Velez I; Biryukov SS; Cote CK; Berisio R; Lukomski S
    Vaccines (Basel); 2021 Oct; 9(11):. PubMed ID: 34835150
    [No Abstract]   [Full Text] [Related]  

  • 2. Intranasal immunization with a Bucl8-based vaccine ameliorates bacterial burden and pathological inflammation, and promotes an IgG2a/b dominant response in an outbred mouse model of
    Grund M; Choi SJ; Powell L; Lukomski S
    Front Immunol; 2023; 14():1177650. PubMed ID: 37545515
    [No Abstract]   [Full Text] [Related]  

  • 3. Burkholderia collagen-like protein 8, Bucl8, is a unique outer membrane component of a putative tetrapartite efflux pump in Burkholderia pseudomallei and Burkholderia mallei.
    Grund ME; Choi SJ; McNitt DH; Barbier M; Hu G; LaSala PR; Cote CK; Berisio R; Lukomski S
    PLoS One; 2020; 15(11):e0242593. PubMed ID: 33227031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burkholderia pseudomallei Δ
    Khakhum N; Bharaj P; Myers JN; Tapia D; Kilgore PB; Ross BN; Walker DH; Endsley JJ; Torres AG
    mSphere; 2019 Jan; 4(1):. PubMed ID: 30602524
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis.
    Burtnick MN; Shaffer TL; Ross BN; Muruato LA; Sbrana E; DeShazer D; Torres AG; Brett PJ
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 29109172
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis.
    Schully KL; Bell MG; Prouty AM; Gallovic MD; Gautam S; Peine KJ; Sharma S; Bachelder EM; Pesce JT; Elberson MA; Ainslie KM; Keane-Myers A
    Int J Pharm; 2015 Nov; 495(2):849-61. PubMed ID: 26428631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates.
    Baker SM; Davitt CJH; Motyka N; Kikendall NL; Russell-Lodrigue K; Roy CJ; Morici LA
    Vaccines (Basel); 2017 Dec; 5(4):. PubMed ID: 29232837
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multi-component vaccine approaches for Burkholderia pseudomallei.
    Morici L; Torres AG; Titball RW
    Clin Exp Immunol; 2019 May; 196(2):178-188. PubMed ID: 30963550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis.
    Casey WT; Spink N; Cia F; Collins C; Romano M; Berisio R; Bancroft GJ; McClean S
    Vaccine; 2016 May; 34(23):2616-21. PubMed ID: 27091689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.
    Nieves W; Petersen H; Judy BM; Blumentritt CA; Russell-Lodrigue K; Roy CJ; Torres AG; Morici LA
    Clin Vaccine Immunol; 2014 May; 21(5):747-54. PubMed ID: 24671550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shotgun Immunoproteomic Approach for the Discovery of Linear B-Cell Epitopes in Biothreat Agents
    D'haeseleer P; Collette NM; Lao V; Segelke BW; Branda SS; Franco M
    Front Immunol; 2021; 12():716676. PubMed ID: 34659206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.
    Silva EB; Goodyear A; Sutherland MD; Podnecky NL; Gonzalez-Juarrero M; Schweizer HP; Dow SW
    Infect Immun; 2013 Dec; 81(12):4626-34. PubMed ID: 24101688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
    Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R
    PLoS One; 2007 Oct; 2(10):e1018. PubMed ID: 17925866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.
    Nieves W; Asakrah S; Qazi O; Brown KA; Kurtz J; Aucoin DP; McLachlan JB; Roy CJ; Morici LA
    Vaccine; 2011 Oct; 29(46):8381-9. PubMed ID: 21871517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response.
    Wei J; Versteeg L; Liu Z; Keegan B; Gazzinelli-Guimarães AC; Fujiwara RT; Briggs N; Jones KM; Strych U; Beaumier CM; Bottazzi ME; Hotez PJ; Zhan B
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005769. PubMed ID: 28708895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.
    Moustafa DA; Scarff JM; Garcia PP; Cassidy SK; DiGiandomenico A; Waag DM; Inzana TJ; Goldberg JB
    PLoS One; 2015; 10(7):e0132032. PubMed ID: 26148026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.
    Muruato LA; Tapia D; Hatcher CL; Kalita M; Brett PJ; Gregory AE; Samuel JE; Titball RW; Torres AG
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28903988
    [No Abstract]   [Full Text] [Related]  

  • 20. Reverse vaccinology and subtractive genomics-based putative vaccine targets identification for Burkholderia pseudomallei Bp1651.
    Hizbullah ; Nazir Z; Afridi SG; Shah M; Shams S; Khan A
    Microb Pathog; 2018 Dec; 125():219-229. PubMed ID: 30243554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.